Koster, D.

patient fibatide resource treatment resource consumption trial european ffectivenes hospital epti fibatide infarction cost-e ffectiveness ratios country consumption pursuit month cost e ffectiveness 6 months placebo european patients cost-e syndrome 30 days di fference pursuit trial intervention cost cost /yols epti fibatide patients survival ratio analysis fference death procedure outcome group platelet end-point heart table analyses eur heart j resource use event arteriography /iiia epti fibatide use health angina life expectancy investigator population percutaneou management receptor study di fferences glycoprotein 0·001 disease discount mi =myocardial infarction europe arteriography rate countries technology creatine kinase treatment costs treatment groups patient outcomes european countries issue january elevation e ffects fferent germany length measure expectancy artery